These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 18056630)

  • 1. Structural basis for reduced FGFR2 activity in LADD syndrome: Implications for FGFR autoinhibition and activation.
    Lew ED; Bae JH; Rohmann E; Wollnik B; Schlessinger J
    Proc Natl Acad Sci U S A; 2007 Dec; 104(50):19802-7. PubMed ID: 18056630
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lacrimo-auriculo-dento-digital syndrome is caused by reduced activity of the fibroblast growth factor 10 (FGF10)-FGF receptor 2 signaling pathway.
    Shams I; Rohmann E; Eswarakumar VP; Lew ED; Yuzawa S; Wollnik B; Schlessinger J; Lax I
    Mol Cell Biol; 2007 Oct; 27(19):6903-12. PubMed ID: 17682060
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mutations in different components of FGF signaling in LADD syndrome.
    Rohmann E; Brunner HG; Kayserili H; Uyguner O; Nürnberg G; Lew ED; Dobbie A; Eswarakumar VP; Uzumcu A; Ulubil-Emeroglu M; Leroy JG; Li Y; Becker C; Lehnerdt K; Cremers CW; Yüksel-Apak M; Nürnberg P; Kubisch C; Schlessinger J; van Bokhoven H; Wollnik B
    Nat Genet; 2006 Apr; 38(4):414-7. PubMed ID: 16501574
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lacrimo-auriculo-dento-digital syndrome: A novel mutation in a Korean family and review of literature.
    Ryu YH; Kyun Chae J; Kim JW; Lee S
    Mol Genet Genomic Med; 2020 Oct; 8(10):e1412. PubMed ID: 32715658
    [TBL] [Abstract][Full Text] [Related]  

  • 5. LADD syndrome with glaucoma is caused by a novel gene.
    Simpson A; Avdic A; Roos BR; DeLuca A; Miller K; Schnieders MJ; Scheetz TE; Alward WL; Fingert JH
    Mol Vis; 2017; 23():179-184. PubMed ID: 28400699
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A molecular brake in the kinase hinge region regulates the activity of receptor tyrosine kinases.
    Chen H; Ma J; Li W; Eliseenkova AV; Xu C; Neubert TA; Miller WT; Mohammadi M
    Mol Cell; 2007 Sep; 27(5):717-30. PubMed ID: 17803937
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The N550K/H mutations in FGFR2 confer differential resistance to PD173074, dovitinib, and ponatinib ATP-competitive inhibitors.
    Byron SA; Chen H; Wortmann A; Loch D; Gartside MG; Dehkhoda F; Blais SP; Neubert TA; Mohammadi M; Pollock PM
    Neoplasia; 2013 Aug; 15(8):975-88. PubMed ID: 23908597
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of covalent inhibitors that can overcome resistance to first-generation FGFR kinase inhibitors.
    Tan L; Wang J; Tanizaki J; Huang Z; Aref AR; Rusan M; Zhu SJ; Zhang Y; Ercan D; Liao RG; Capelletti M; Zhou W; Hur W; Kim N; Sim T; Gaudet S; Barbie DA; Yeh JR; Yun CH; Hammerman PS; Mohammadi M; Jänne PA; Gray NS
    Proc Natl Acad Sci U S A; 2014 Nov; 111(45):E4869-77. PubMed ID: 25349422
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TAS-120 Overcomes Resistance to ATP-Competitive FGFR Inhibitors in Patients with FGFR2 Fusion-Positive Intrahepatic Cholangiocarcinoma.
    Goyal L; Shi L; Liu LY; Fece de la Cruz F; Lennerz JK; Raghavan S; Leschiner I; Elagina L; Siravegna G; Ng RWS; Vu P; Patra KC; Saha SK; Uppot RN; Arellano R; Reyes S; Sagara T; Otsuki S; Nadres B; Shahzade HA; Dey-Guha I; Fetter IJ; Baiev I; Van Seventer EE; Murphy JE; Ferrone CR; Tanabe KK; Deshpande V; Harding JJ; Yaeger R; Kelley RK; Bardelli A; Iafrate AJ; Hahn WC; Benes CH; Ting DT; Hirai H; Getz G; Juric D; Zhu AX; Corcoran RB; Bardeesy N
    Cancer Discov; 2019 Aug; 9(8):1064-1079. PubMed ID: 31109923
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A requirement for Fgfr2 in middle ear development.
    Rigueur D; Roberts RR; Bobzin L; Merrill AE
    Genesis; 2019 Jan; 57(1):e23252. PubMed ID: 30253032
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pathogenic Cysteine Removal Mutations in FGFR Extracellular Domains Stabilize Receptor Dimers and Perturb the TM Dimer Structure.
    Sarabipour S; Hristova K
    J Mol Biol; 2016 Oct; 428(20):3903-3910. PubMed ID: 27596331
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Functional characterization of a novel FGFR2 mutation, E731K, in craniosynostosis.
    Park J; Park OJ; Yoon WJ; Kim HJ; Choi KY; Cho TJ; Ryoo HM
    J Cell Biochem; 2012 Feb; 113(2):457-64. PubMed ID: 21928350
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Elucidating the Role of Wildtype and Variant FGFR2 Structural Dynamics in (Dys)Function and Disorder.
    Lian Y; Bodian D; Shehu A
    Int J Mol Sci; 2024 Apr; 25(8):. PubMed ID: 38674107
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Asymmetric tyrosine kinase arrangements in activation or autophosphorylation of receptor tyrosine kinases.
    Bae JH; Schlessinger J
    Mol Cells; 2010 May; 29(5):443-8. PubMed ID: 20432069
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Two FGF Receptor Kinase Molecules Act in Concert to Recruit and Transphosphorylate Phospholipase Cγ.
    Huang Z; Marsiglia WM; Basu Roy U; Rahimi N; Ilghari D; Wang H; Chen H; Gai W; Blais S; Neubert TA; Mansukhani A; Traaseth NJ; Li X; Mohammadi M
    Mol Cell; 2016 Jan; 61(1):98-110. PubMed ID: 26687682
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A novel mode of protein kinase inhibition exploiting hydrophobic motifs of autoinhibited kinases: discovery of ATP-independent inhibitors of fibroblast growth factor receptor.
    Eathiraj S; Palma R; Hirschi M; Volckova E; Nakuci E; Castro J; Chen CR; Chan TC; France DS; Ashwell MA
    J Biol Chem; 2011 Jun; 286(23):20677-87. PubMed ID: 21454610
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structural basis for fibroblast growth factor receptor 2 activation in Apert syndrome.
    Ibrahimi OA; Eliseenkova AV; Plotnikov AN; Yu K; Ornitz DM; Mohammadi M
    Proc Natl Acad Sci U S A; 2001 Jun; 98(13):7182-7. PubMed ID: 11390973
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phosphorylation and lipid raft association of fibroblast growth factor receptor-2 in oligodendrocytes.
    Bryant MR; Marta CB; Kim FS; Bansal R
    Glia; 2009 Jul; 57(9):935-46. PubMed ID: 19053057
    [TBL] [Abstract][Full Text] [Related]  

  • 19. LADD syndrome is caused by FGF10 mutations.
    Milunsky JM; Zhao G; Maher TA; Colby R; Everman DB
    Clin Genet; 2006 Apr; 69(4):349-54. PubMed ID: 16630169
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phosphorylation of serine 779 in fibroblast growth factor receptor 1 and 2 by protein kinase C(epsilon) regulates Ras/mitogen-activated protein kinase signaling and neuronal differentiation.
    Lonic A; Powell JA; Kong Y; Thomas D; Holien JK; Truong N; Parker MW; Guthridge MA
    J Biol Chem; 2013 May; 288(21):14874-85. PubMed ID: 23564461
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.